Samsung Biologics announced on May 22 that it will spin off its biosimilar unit, Samsung Bioepis, to create a new holding company tentatively named Samsung Epis Holdings. The new company will oversee subsidiaries and focus on new investments.
The move separates Samsung Biologics’ core contract development and manufacturing (CDMO) business from Samsung Bioepis, which develops biosimilar drugs.
Samsung Bioepis was founded in 2012 as a joint venture between Samsung Biologics and U.S.-based Biogen, with Samsung holding an 85% stake and Biogen 15%. In 2022, Samsung Biologics acquired Biogen’s entire stake, making Bioepis a wholly owned subsidiary.
With the spin-off, Samsung Biologics will focus solely on its CDMO operations. Samsung Epis Holdings, as a pure holding company, will fully own Samsung Bioepis and lead its biosimilar business.
“This new structure will allow for faster and more specialized decision-making tailored to each business’s strategy and operations,” the company said.
